Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...
GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM ...
The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.
The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.
Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
Lerochol is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
The CDC reported that COVID vaccines reduced the risk of ER visits by 76% in kids under age 4 and by 56% in kids ages 5 to 17 during the first 6 months after vaccination. (HealthDay News) — COVID-19 ...
Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Daybue Stix, a strawberry-flavored trofinetide powder mixable with water-based liquids, gains FDA approval for Rett syndrome treatment.
HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...
HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback